EMA Executive Director Guido Rasi Takes Office
The new executive director of the European Medicines Agency begins appointment.
Professor Guido Rasi has begun his five-year appointment as executive director of the European Medicines Agency (EMA). Rasi was nominated for the position on Oct. 1, 2015 and was appointed Oct. 13, 2015. Rasi served previously as executive director of EMA from November 2011–November 2014.
“I am very happy to be back at the helm of the Agency,” Rasi said in a press release. “We are currently undergoing the most significant transformation of the system of medicine development and authorization that I have seen during my 35-year career in public health, either as a doctor, a researcher or a regulator. It is exciting and challenging to be leading the Agency during this time.”
Professor Rasi previously served as EMA’s principal adviser in charge of strategy and was the director-general of the Italian Medicines Agency from 2008 to
2011. He also worked at the Institute for Experimental Medicine of the National Research Council, Italy and was the director of the Institute of Molecular Medicine of the National Research Council in Rome. Professor Rasi holds a degree in medicine and surgery, with specializations in internal medicine, allergology, and clinical immunology from the University of Rome.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
